Skip to main content
. 2020 Nov 13;39(6):619–630. doi: 10.1007/s10930-020-09942-9

Table 3.

Names, structures and known therapeutics of top 10 candidates in this study

ID Name Therapeutic agent Structures
BRC1213 (top 1) Folic acid (Vit. B9)

Dietary supplements

Hematologic, vitamins

 graphic file with name 10930_2020_9942_Figa_HTML.gif
BRC0679 (top 2) Telmisartan Antihypertensive graphic file with name 10930_2020_9942_Figb_HTML.gif
BRC0089 (top 3) Methotrexate Antineoplastic graphic file with name 10930_2020_9942_Figc_HTML.gif
BRC0206 (top 4) Bosentan Antihypertensive graphic file with name 10930_2020_9942_Figd_HTML.gif
BRC0332 (top 5) Lapatinib Anticancer graphic file with name 10930_2020_9942_Fige_HTML.gif
BRC0205 (top 6) Gefitinib

Antineoplastic

BCRP/ABCG2 inhibitors

 graphic file with name 10930_2020_9942_Figf_HTML.gif
BRC0901 (top 7) Ketoconazole Anti-infective graphic file with name 10930_2020_9942_Figg_HTML.gif
BRC0853 (top 8) Carvedilol Antihypertensive vasodilator agent graphic file with name 10930_2020_9942_Figh_HTML.gif
BRC0377 (top 9) Glyburide Antihyperglycemic graphic file with name 10930_2020_9942_Figi_HTML.gif
BRC1908 (top 10) Avanafil

Urologicals

Vasodilating

 graphic file with name 10930_2020_9942_Figj_HTML.gif